{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:1146",
      "entity_text" : "TMA",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:60750",
      "entity_text" : "gemcitabine",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Thrombocytopenia and anemia from bone marrow suppression are common side effects of gemcitabine, but the first case of gemcitabine induced TMA was reported in 1994 during an ongoing phase II clinical trial for pancreatic adenocarcinoma 8.",
  "reading_complete" : "2020-08-03T14:58:57Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T14:58:18Z",
  "trigger" : "induced",
  "evidence" : [ "gemcitabine-induced TMA" ],
  "pmc_id" : "5715608",
  "score" : 0
}